Abstract

SEMG1 and SEMG2 genes belong to the family of cancer-testis antigens (CTAs), whose expression normally is restricted to male germ cells but is often restored in various malignancies. High levels of SEMG1 and SEMG2 expression are detected in prostate, renal, and lung cancer as well as hemoblastosis. However, the functional importance of both SEMGs proteins in human neoplasms is still largely unknown. In this study, by using a combination of the bioinformatics and various cellular and molecular assays, we have demonstrated that SEMG1 and SEMG2 are frequently expressed in lung cancer clinical samples and cancer cell lines of different origins and are negatively associated with the survival rate of cancer patients. Using the pull-down assay followed by LC-MS/MS mass-spectrometry, we have identified 119 proteins associated with SEMG1 and SEMG2. Among the SEMGs interacting proteins we noticed two critical glycolytic enzymes-pyruvate kinase M2 (PKM2) and lactate dehydrogenase A (LDHA). Importantly, we showed that SEMGs increased the protein level and activity of both PKM2 and LDHA. Further, both SEMGs increased the membrane mitochondrial potential (MMP), glycolysis, respiration, and ROS production in several cancer cell lines. Taken together, these data provide first evidence that SEMGs can up-regulate the energy metabolism of cancer cells, exemplifying their oncogenic features.

Highlights

  • The family of cancer-testis antigens (CTAs) encompasses more than 200 tumor-associated antigens, which normally express in testis and placenta and function in reproduction

  • We have shown that SEMG1 and SEMG2 are observed at different frequencies in various human cancer cell lines and are associated with poor prognosis for survival of patients

  • SEMG1 and SEMG2 are frequently over-expressed in human cancer cell models and clinical samples of lung cancer

Read more

Summary

Introduction

The family of cancer-testis antigens (CTAs) encompasses more than 200 tumor-associated antigens, which normally express in testis and placenta and function in reproduction. CTA-coding genes become derepressed in transformed non-germ cells. Over-expression of CTAs is preferentially associated with poorly differentiated, metastatic tumors, which makes them a predictive marker of unfavorable survival prognosis for cancer patients[1,2]. When de-repressed in non-germ cells, CTAs often serve as markers of specific immune activation since testis are immune-privileged organs and testis-specific proteins are immunogenic when they are expressed in tumors[3]. A number of CTAs are considered as candidates for immune therapy[4,5]. X-linked CTAs (MAGE-A3, NY-ESO-1, etc) have been used in clinical trials as immune vaccines[6] and they are generally better studied in the context of tumor biology

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call